Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, has raised a $25M Series A

Companies building AI tools to predict patient outcomes from medical scans can now access significant venture capital.

Altis Labs, an AI software company focused on drug development, announced it has secured $25 million in Series A funding. The company's AI model is designed to analyze CT scans generated during oncology clinical trials. It then provides predictions linked to patient survival outcomes. The funding round was confirmed by CEO Felix Baldauf-Lenschen in a statement to Axios Pro. This capital infusion is expected to support Altis Labs' continued development and deployment of its predictive AI technology within the pharmaceutical and biotechnology sectors, particularly in accelerating cancer research and treatment discovery.

The $25 million Series A funding for Altis Labs highlights a growing investor appetite for AI applications in drug discovery and clinical trial optimization. Companies leveraging AI to extract predictive insights from medical imaging, such as CT scans, are positioning themselves to de-risk and accelerate the lengthy and expensive drug development process. This trend suggests a shift towards data-driven decision-making in oncology research, where AI's ability to forecast patient survival could significantly impact trial design and therapeutic selection.

This development affects pharmaceutical companies and contract research organizations by offering tools that could streamline patient stratification and identify promising drug candidates faster. Investors are clearly signaling that AI's role in interpreting complex medical data for therapeutic prediction is a key area for future growth. The successful funding of Altis Labs may spur further innovation and competition in the AI-powered drug development space, potentially leading to new partnerships and advancements in patient care.